It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileXYLO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 5 TA indicator(s) are bullish while XYLO’s TA Score has 5 bullish TA indicator(s).
AZTA (@Pharmaceuticals: Other) experienced а +4.68% price change this week, while XYLO (@Medical/Nursing Services) price change was -1.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.53%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +4.24%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +4.58%.
AZTA is expected to report earnings on Nov 18, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
AZTA | XYLO | AZTA / XYLO | |
Capitalization | 1.39B | 6.57M | 21,196% |
EBITDA | 13.8M | -16.3M | -85% |
Gain YTD | -39.220 | 41.713 | -94% |
P/E Ratio | N/A | N/A | - |
Revenue | 669M | 91.7M | 730% |
Total Cash | 328M | 9.36M | 3,505% |
Total Debt | 53.7M | 9.79M | 549% |
AZTA | XYLO | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 48 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 96 | |
PRICE GROWTH RATING 1..100 | 64 | 51 | |
P/E GROWTH RATING 1..100 | 55 | 49 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XYLO's Valuation (1) in the Medical Specialties industry is significantly better than the same rating for AZTA (70) in the Electronic Production Equipment industry. This means that XYLO’s stock grew significantly faster than AZTA’s over the last 12 months.
XYLO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that XYLO’s stock grew similarly to AZTA’s over the last 12 months.
AZTA's SMR Rating (91) in the Electronic Production Equipment industry is in the same range as XYLO (96) in the Medical Specialties industry. This means that AZTA’s stock grew similarly to XYLO’s over the last 12 months.
XYLO's Price Growth Rating (51) in the Medical Specialties industry is in the same range as AZTA (64) in the Electronic Production Equipment industry. This means that XYLO’s stock grew similarly to AZTA’s over the last 12 months.
XYLO's P/E Growth Rating (49) in the Medical Specialties industry is in the same range as AZTA (55) in the Electronic Production Equipment industry. This means that XYLO’s stock grew similarly to AZTA’s over the last 12 months.
AZTA | XYLO | |
---|---|---|
RSI ODDS (%) | 3 days ago73% | N/A |
Stochastic ODDS (%) | 3 days ago69% | 3 days ago82% |
Momentum ODDS (%) | 3 days ago78% | 3 days ago80% |
MACD ODDS (%) | 3 days ago79% | 3 days ago90% |
TrendWeek ODDS (%) | 3 days ago71% | 3 days ago89% |
TrendMonth ODDS (%) | 3 days ago82% | 3 days ago85% |
Advances ODDS (%) | 5 days ago71% | 3 days ago82% |
Declines ODDS (%) | 3 days ago84% | 5 days ago88% |
BollingerBands ODDS (%) | 3 days ago87% | 3 days ago90% |
Aroon ODDS (%) | 3 days ago81% | N/A |
1 Day | |||
---|---|---|---|
STOCK / NAME | Price $ | Chg $ | Chg % |
ENTX | 2.00 | 0.03 | +1.52% |
Entera Bio Ltd | |||
IHS | 7.04 | 0.08 | +1.15% |
IHS Holding Limited | |||
SBS | 21.59 | -0.11 | -0.51% |
Companhia DE Saneamento B Sico DO Estado DE SAO Paulo-Sabesp Ads's | |||
SMX | 4.91 | -0.07 | -1.41% |
SMX (Security Matters) Public Limited Company | |||
CTKB | 4.01 | -0.07 | -1.72% |
Cytek Biosciences |
A.I.dvisor tells us that XYLO and EXAS have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XYLO and EXAS's prices will move in lockstep.
Ticker / NAME | Correlation To XYLO | 1D Price Change % | ||
---|---|---|---|---|
XYLO | 100% | +2.18% | ||
EXAS - XYLO | 23% Poorly correlated | +1.36% | ||
VVOS - XYLO | 23% Poorly correlated | -10.85% | ||
WAT - XYLO | 23% Poorly correlated | -0.67% | ||
AZTA - XYLO | 23% Poorly correlated | -0.65% | ||
XGN - XYLO | 22% Poorly correlated | +1.55% | ||
More |